[1] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[2] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[3] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[4] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[5] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[6] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[7] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[8] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[9] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[10] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[11] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[12] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[13] |
ZHENG Jinfeng, WANG Jinghong.
Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
|
[14] |
SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying.
Pharmaceutical care of a patient with indapamide-induced agranulocytosis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
|
[15] |
WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui.
Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
|